Research has resulted in regulatory approval of nine agents for acute myeloid leukaemia
indications by the US Food and Drug Administration since 2017: the Bcl-2 inhibitor …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

The 5-year overall survival rate of AML patients remains 25–40%. The prognosis is even
more dismal for older patients who are ineligible for intensive chemotherapy and patients …

Background: The limit of acceptable toxicity for standard chemotherapeutic drugs used in
acute myeloid leukaemia (AML) therapy has been reached. New therapeutic strategies are …

Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for
patients with AML was limited to induction chemotherapy with cytarabine and anthracycline …

Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …

Precision medicine is gaining importance in the treatment of acute myeloid leukemia (AML).
Objectively reviewing past and current knowledge aids guiding future research. Therefore …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

Acute myeloid leukaemia (AML) is the most common form of leukaemia in young adults.
Although 75–85% of patients will achieve complete remission after induction chemotherapy …